Applied Radiology

MRI · Workflow · Medical Imaging · Information Technology · Artificial Intelligence

Philips Submits BlueSeal Horizon 3.0T MRI for FDA Clearance

November 18, 2026 · News Release

Source: Philips

Philips Submits BlueSeal Horizon 3.0T MRI for FDA Clearance

Philips has submitted its BlueSeal Horizon SI, XI, and ZI 3.0T MRI systems to the US Food and Drug Administration (FDA) for 510(k) clearance. This submission represents the first 3.0T high-performance helium-free MRI platform, expanding the Philips BlueSeal portfolio into higher field strengths.

The BlueSeal Horizon MRI systems include a variety of advanced features, as well as next-generation clinical AI solutions designed to enhance multiple specialties, streamline workflows, and aid clinical decision-making. Philips has been at the forefront of developing helium-free MRI technology since 2018, starting with its BlueSeal 1.5T systems, of which over 2,500 units have been installed globally. This has resulted in the conservation of more than 7 million liters of liquid helium, mitigating the need for helium refills and vent pipes and simplifying installation processes along with lifecycle management.

"The FDA submission of BlueSeal Horizon marks an important step toward bringing the benefits of helium-free 3.0T MRI to more healthcare providers and patients," said Ioannis Panagiotelis, PhD, Business Leader, MR at Philips. He emphasized the significance of innovation and resilience in response to the increasing demand for MRI, highlighting the platform's role in facilitating improved care delivery for radiology teams and patients alike.

Philips will showcase its MR portfolio and the BlueSeal technology at the RSNA 2026 conference in Chicago. The innovations aim to enhance workflow efficiency and support accurate diagnostic outcomes, allowing healthcare providers to focus their expertise more effectively. Attendees can visit the Philips booth (#6730) for additional information.

More in MRI